These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25185736)

  • 41. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
    Henderson PK; Herrera JL
    Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review article: the current pharmacological therapies for hepatic encephalopathy.
    Bass NM
    Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():23-31. PubMed ID: 17295849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
    Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
    Pedretti G; Calzetti C; Missale G; Fiaccadori F
    Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ammonia abolishers: antibiotics for hepatic encephalopathy.
    Felicilda-Reynaldo RF
    Medsurg Nurs; 2012; 21(3):173-5; quiz 176. PubMed ID: 22866441
    [No Abstract]   [Full Text] [Related]  

  • 53. Rifaximin treatment in hepatic encephalopathy.
    Wang CC; Kao JH
    N Engl J Med; 2010 Jun; 362(25):2423; author reply 2424-5. PubMed ID: 20573932
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of hepatic encephalopathy with rifaximin: more to think about.
    Gitlin N
    Hepatology; 2011 Mar; 53(3):1059; author reply 1059-60. PubMed ID: 21294145
    [No Abstract]   [Full Text] [Related]  

  • 55. Rifaximin treatment in hepatic encephalopathy.
    Xue T; Qiu JH; Qiao L
    N Engl J Med; 2010 Jun; 362(25):2424; author reply 2424-5. PubMed ID: 20578275
    [No Abstract]   [Full Text] [Related]  

  • 56. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
    Adachi JA; DuPont HL
    Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rifaximin treatment in hepatic encephalopathy.
    Sharma P; Sharma BC
    N Engl J Med; 2010 Jun; 362(25):2423-4; author reply 2424-5. PubMed ID: 20578274
    [No Abstract]   [Full Text] [Related]  

  • 59. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
    Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
    Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin.
    Bruyneel M; Sersté T; Libert W; van den Broecke S; Ameye L; Dachy B; Mulkay JP; Moreno C; Gustot T
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):302-308. PubMed ID: 27977438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.